Pallas Capital Advisors LLC Has $1.46 Million Stake in Bristol Myers Squibb Company $BMY

Pallas Capital Advisors LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 44.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,407 shares of the biopharmaceutical company’s stock after buying an additional 9,972 shares during the period. Pallas Capital Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,462,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BMY. Addison Advisors LLC raised its position in shares of Bristol Myers Squibb by 6.2% during the 3rd quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 232 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in Bristol Myers Squibb by 4.4% in the third quarter. State of New Jersey Common Pension Fund D now owns 713,146 shares of the biopharmaceutical company’s stock valued at $32,163,000 after purchasing an additional 29,826 shares during the last quarter. Hardy Reed LLC lifted its stake in Bristol Myers Squibb by 16.8% in the third quarter. Hardy Reed LLC now owns 7,814 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 1,125 shares during the period. Investment Partners LTD. boosted its holdings in Bristol Myers Squibb by 3.1% during the third quarter. Investment Partners LTD. now owns 12,985 shares of the biopharmaceutical company’s stock worth $586,000 after buying an additional 394 shares during the last quarter. Finally, Aberdeen Group plc grew its position in shares of Bristol Myers Squibb by 2.8% during the 3rd quarter. Aberdeen Group plc now owns 3,180,742 shares of the biopharmaceutical company’s stock worth $142,863,000 after buying an additional 87,382 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $60.28 on Wednesday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The business has a 50-day moving average of $55.70 and a 200-day moving average of $49.72. The stock has a market capitalization of $122.76 billion, a price-to-earnings ratio of 17.47, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMY. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Guggenheim restated a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Citigroup lifted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Finally, HSBC restated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.